Movement Alert|Axon Enterprise, Inc. Rises 5.21% in Regular Trading, Multiple Banks Raise Price Targets Ahead of Q2 Earnings

Market Focus
Jul 28

On July 28, Axon Enterprise, Inc. rose 5.21% in regular trading, trading at $528.59/share, with turnover of $135 million. The rally was driven by multiple investment banks expressing optimism on Q2 bookings growth prospects ahead of the company's August 5 earnings release.

RBC Capital Markets projects Q2 bookings to grow 2.5% year-over-year, supported by accelerating AI adoption, an open ecosystem strategy, and emerging businesses including drones. The firm maintained its outperform rating and $735 price target, noting Axon is well-positioned to sustain revenue growth above 30% as police departments face staffing challenges and budget pressures. Meanwhile, Piper Sandler raised its price target from $674 to $724 with an overweight rating, and Needham significantly lifted its target from $600 to $750. The consensus mean price target stands at approximately $685.71.

Axon reported Q1 revenue of $807.35 million, beating the $778.9 million estimate, and raised full-year guidance to 30%-32% revenue growth. The market appears to be pricing in continued momentum ahead of Q2 results.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10